
CLAIMS

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a compound of Formula I:



Formula I

or a pharmaceutically acceptable salt thereof, a buffer, sodium chloride, and water.

2. The pharmaceutical composition of claim 1, wherein the compound of Formula I is present in the composition in an amount of between about 0.003% and about 1% (w/v).

3. The pharmaceutical composition of claim 2, wherein the compound of Formula I is present in the composition in an amount of about 0.01% (w/v).

4. The pharmaceutical composition of claim 2, wherein the compound of Formula I is present in the composition in an amount of about 0.03% (w/v).

5. The pharmaceutical composition of claim 2, wherein the compound of Formula I is present in the composition in an amount of about 0.1% (w/v).

6. The pharmaceutical composition of claim 2, wherein the compound of Formula I is present in the composition in an amount of about 0.3% (w/v).

7. The pharmaceutical composition of any one of claims 1 to 6, wherein the buffer is a citrate buffer and phosphate buffer.

8. The pharmaceutical composition of claim 7, wherein the citrate buffer comprises citric acid and the phosphate buffer comprises dibasic sodium phosphate.

9. The pharmaceutical composition of claim 8, wherein the citric acid is present in the

composition in an amount of between about 0.01% and 1% (w/v).

10. The pharmaceutical composition of any one of claims 8 or 9, wherein the citric acid is present in the composition in an amount of about 0.1% (w/v).

11. The pharmaceutical composition of any one of claims 8 or 9, wherein the citric acid is present in the composition in an amount of about 0.09% (w/v).

12. The pharmaceutical composition of any one of claims 8 to 11, wherein the dibasic sodium phosphate is present in the composition in an amount of between about 0.01% and 2% (w/v).

13. The pharmaceutical composition of any one of claims 8 to 12, wherein the dibasic sodium phosphate is present in the composition in an amount of about 0.5% (w/v).

14. The pharmaceutical composition of any one of claims 8 to 12, wherein the dibasic sodium phosphate is present in the composition in an amount of about 1% (w/v).

15. The pharmaceutical composition of any one of claims 1 to 14, wherein the sodium chloride is present in the composition in amount of at least 0.6% (w/v).

16. The pharmaceutical composition of any one of claims 1 to 14, wherein the sodium chloride is present in the composition in amount of about 0.6% (w/v).

17. The pharmaceutical composition of any one of claims 1 to 16, wherein the composition has a pH of between about 4.5 and about 8.

18. The pharmaceutical composition of any one of claims 1 to 17, wherein the composition has a pH of between about 6.5 and about 7.6.

19. The pharmaceutical composition of any one of claims 1 to 18, wherein the composition has a pH of about 7.

20. The pharmaceutical composition of claim 1, wherein the compound of Formula I is present in the composition in an amount of about 0.01% (w/v), the sodium chloride is present in the composition in an amount of at least 0.6%, the buffer is a citrate buffer comprising citric acid and a phosphate buffer comprising dibasic sodium phosphate.

21. The pharmaceutical composition of claim 20, wherein the citric acid is present in the composition in amount of about 0.1% (w/v) and the dibasic sodium phosphate is present in the composition in an amount of 1% (w/v).

22. The pharmaceutical composition of claim 20, wherein the citric acid is present in the composition in amount of about 0.09% (w/v) and the dibasic sodium phosphate is present in the composition in an amount of 0.5% (w/v).

23. The pharmaceutical composition of claim 1, wherein the compound of Formula I is present in the composition in an amount of about 0.03% (w/v), the sodium chloride is present in the composition in an amount of at least 0.6%, the buffer is a citrate buffer comprising citric acid and a phosphate buffer comprising dibasic sodium phosphate.

24. The pharmaceutical composition of claim 20, wherein the citric acid is present in the composition in amount of about 0.1% (w/v) and the dibasic sodium phosphate is present in the composition in an amount of 1% (w/v).

25. The pharmaceutical composition of claim 20, wherein the citric acid is present in the composition in amount of about 0.09% (w/v) and the dibasic sodium phosphate is present in the composition in an amount of 0.5% (w/v).

26. The pharmaceutical composition of claim 1, wherein the compound of Formula I is present in the composition in an amount of about 0.1% (w/v), the sodium chloride is present in the composition in an amount of at least 0.6%, the buffer is a citrate buffer comprising citric acid and a phosphate buffer comprising dibasic sodium phosphate.

27. The pharmaceutical composition of claim 20, wherein the citric acid is present in the composition in amount of about 0.1% (w/v) and the dibasic sodium phosphate is present in the composition in an amount of 1% (w/v).

28. The pharmaceutical composition of claim 20, wherein the citric acid is present in the composition in amount of about 0.09% (w/v) and the dibasic sodium phosphate is present in the composition in an amount of 0.5% (w/v).

29. The pharmaceutical composition of claim 1, wherein the compound of Formula I is present

in the composition in an amount of about 0.3% (w/v), the sodium chloride is present in the composition in an amount of at least 0.6%, the buffer is a citrate buffer comprising citric acid and a phosphate buffer comprising dibasic sodium phosphate.

30. The pharmaceutical composition of claim 16, wherein the citric acid is present in the composition in amount of about 0.1% (w/v) and the dibasic sodium phosphate is present in the composition in an amount of 1% (w/v).

31. The pharmaceutical composition of claim 16, wherein the citric acid is present in the composition in amount of about 0.09% (w/v) and the dibasic sodium phosphate is present in the composition in an amount of 0.5% (w/v).

32. A method of treating an ocular condition in an individual in need of such treatment, the method comprising administering to the individual the pharmaceutical composition of any one of claims 1 to 31, and wherein the ocular condition is selected from the group consisting of presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and night myopia.

33. The method of claim 32, wherein the ocular condition is presbyopia.

34. The method of claim 32, wherein the ocular condition is poor night vision.

35. The method of claim 32, wherein the ocular condition is visual glare.

36. The method of claim 33, wherein the ocular condition is visual starbursts.

37. The method of claim 33, wherein the ocular condition is visual halos.

38. The method of claim 33, wherein the ocular condition is night myopia.

39. The method of any one of claims 32 to 38, wherein the pharmaceutical composition is administered to one or both eyes of the individual.

40. The method of claim 39, wherein the administration to the eye is topical administration.

41. The method of any one of claim 33 to 40, wherein the compound of Formula I or pharmaceutically acceptable salt thereof, when administered to the individual, has binding to the

iris pigment that is less than the binding to the iris pigment exhibited by brimonidine.

42. The method of any one of claims 33 to 40, wherein the amount of the compound of Formula I or pharmaceutically acceptable salt thereof is an amount that is less than the amount of brimonidine needed to achieve the same therapeutic effects.

43. The method of any one of claims 33 to 40, wherein the pharmaceutical composition, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of between 2 and 3 mm.

44. The method of any one of claims 33 to 40, wherein the pharmaceutical composition, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of 3 mm or less.

45. The method of any one of claims 33 to 40, wherein the pharmaceutical composition, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of 2.5 mm or less.

46. The method of any one of claims 33 to 40, wherein the pharmaceutical composition, when administered to the individual, causes an improvement in near visual acuity.

47. The method of any one of claims 33 to 40, wherein the pharmaceutical composition, when administered to the individual, causes an improvement in intermediate visual acuity.

48. The method of any one of claims 33 to 40, wherein the pharmaceutical composition, when administered to the individual, causes an improvement in distance visual acuity.

49. The method of any one of claims 46 to 48, where in the improvement in visual acuity is an at least 2-line improvement.

50. The method of any one of claims 46 to 48, where in the improvement in visual acuity is an at least 3-line improvement.

51. The method of any one of claims 43 to 50, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 1 hour.

52. The method of any one of claims 43 to 50, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 2 hours.

53. The method of any one of claims 43 to 50, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 4 hours.

54. The method of any one of claims 43 to 50, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 6 hours.

55. The method of any one of claims 43 to 50, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 9 hours.

56. The method of any one of claims 43 to 50, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 10 hours.

57. The method of any one of claims 43 to 50, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 12 hours.

58. The method of any one of claims 43 to 50, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 200 cd/m^2.

59. The method of any one of claims 43 to 50, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 150 cd/m^2.

60. The method of any one of claims 43 to 50, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 100 cd/m^2.

61. The method of any one of claims 43 to 60, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 50 cd/m^2.

62. The method of any one of claims 43 to 60, wherein the reduction in pupil size or

improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 10 cd/m^2.

63. The method of any one of claims 43 to 60, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 5 cd/m^2.

64. The method of any one of claims 43 to 60, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 2 cd/m^2.

65. The pharmaceutical composition of any one of claims 1 to 31 for use in a method of treating an ocular condition in an individual in need thereof, the method comprising administering the pharmaceutical composition to the individual, and wherein the ocular condition is selected from the group consisting of presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and night myopia.

66. The pharmaceutical composition for use according to claim 65, wherein the ocular condition is presbyopia.

67. The pharmaceutical composition for use according to claim 65, wherein the ocular condition is poor night vision.

68. The pharmaceutical composition for use according to claim 65, wherein the ocular condition is visual glare.

69. The pharmaceutical composition for use according to claim 65, wherein the ocular condition is visual starbursts.

70. The pharmaceutical composition for use according to claim 65, wherein the ocular condition is visual halos.

71. The pharmaceutical composition for use according to claim 65, wherein the ocular condition is night myopia.

72. The pharmaceutical composition for use according to any one of claims 65 to 71, wherein the pharmaceutical composition is administered to one or both eyes of the individual.

73. The compound or pharmaceutically acceptable salt thereof for use according to claim 72, wherein the administration to the eye is topical administration.

74. The pharmaceutical composition for use according to any one of claims 65 to 73, wherein the amount of the compound of Formula I or pharmaceutically acceptable salt thereof, when administered to the individual, has binding to the iris pigment that is less than the binding to the iris pigment exhibited by brimonidine.

75. The pharmaceutical composition for use according to any one of claims 65 to 73, wherein the amount of the compound of Formula I or pharmaceutically acceptable salt thereof is an amount that is less than the amount of brimonidine needed to achieve the same therapeutic effects.

76. The pharmaceutical composition for use according to any one of claims 65 to 73, wherein the pharmaceutical composition, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of between 2 and 3 mm.

77. The pharmaceutical composition for use according to any one of claims 65 to 73, wherein the pharmaceutical composition, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of 3 mm or less.

78. The pharmaceutical composition for use according to any one of claims 65 to 73, wherein the pharmaceutical composition, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of 2.5 mm or less.

79. The pharmaceutical composition for use according to any one of claim 65 to 73, wherein the pharmaceutical composition, when administered to the individual, causes an improvement in near visual acuity.

80. The pharmaceutical composition for use according to any one of claims 65 to 73, wherein the pharmaceutical composition, when administered to the individual, causes an improvement in intermediate visual acuity.

81. The pharmaceutical composition for use according to any one of claims 65 to 73, wherein the pharmaceutical composition, when administered to the individual, causes an improvement in distance visual acuity.

82. The pharmaceutical composition for use according to any one of claims 79 to 81, wherein the improvement in visual acuity is an at least 2-line improvement.

83. The pharmaceutical composition for use according to any one of claims 79 to 81, wherein the improvement in visual acuity is an at least 3-line improvement.

84. The pharmaceutical composition for use according to any one of claims 76 to 83, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 1 hour.

85. The pharmaceutical composition for use according to any one of claims 76 to 83, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 2 hours.

86. The pharmaceutical composition for use according to any one of claims 76 to 83, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 4 hours.

87. The pharmaceutical composition for use according to any one of claims 76 to 83, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 6 hours.

88. The pharmaceutical composition for use according to any one of claims 76 to 83, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 9 hours.

89. The pharmaceutical composition for use according to any one of claims 76 to 83, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 10 hours.

90. The pharmaceutical composition for use according to any one of claims 76 to 83, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 12 hours.

91. The pharmaceutical composition for use according to any one of claims 76 to 90, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 200 cd/m^2.

92. The pharmaceutical composition for use according to any one of claims 76 to 90, wherein

the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 150 cd/m^2.

93. The pharmaceutical composition for use according to any one of claims 76 to 90, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 100 cd/m^2.

94. The pharmaceutical composition for use according to any one of claims 76 to 90, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 50 cd/m^2.

95. The pharmaceutical composition for use according to any one of claims 76 to 90, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 10 cd/m^2.

96. The pharmaceutical composition for use according to any one of claims 76 to 90, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 5 cd/m^2.

97. The pharmaceutical composition for use according to any one of claims 76 to 90, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 2 cd/m^2.

98. Use of the pharmaceutical composition of any one of claims 1 to 31 in a method of treating an ocular condition in an individual in need thereof, the method comprising administering the pharmaceutical composition to the individual, and wherein the ocular condition is selected from the group consisting of presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and night myopia.

99. The use according to claim 98, wherein the ocular condition is presbyopia.

100. The use according to claim 98, wherein the ocular condition is poor night vision.

101. The use according to claim 98, wherein the ocular condition is visual glare.

102. The use according to claim 98, wherein the ocular condition is visual starbursts.

103. The use according to claim 98, wherein the ocular condition is visual halos.

104. The use according to claim 98, wherein the ocular condition is night myopia.

105. The use according to any one of claims 98 to 104, wherein the pharmaceutical composition is administered to one or both eyes of the individual.

106. The use according to claim 105, wherein the administration to the eye is topical administration.

107. The use according to any one of claims 98 to 106, wherein the amount of the compound of Formula I or pharmaceutically acceptable salt thereof, when administered to the individual, has binding to the iris pigment that is less than the binding to the iris pigment exhibited by brimonidine.

108. The use according to any one of claims 98 to 106, wherein the amount of the compound of Formula I or pharmaceutically acceptable salt thereof is an amount that is less than the amount of brimonidine needed to achieve the same therapeutic effects.

109. The use according to any one of claims 98 to 106, wherein the pharmaceutical composition, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of between 2 and 3 mm.

110. The use according to any one of claims 98 to 106, wherein the pharmaceutical composition, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of 3 mm or less.

111. The use according to any one of claims 98 to 106, wherein the pharmaceutical composition, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of 2.5 mm or less.

112. The use according to any one of claims 98 to 106, wherein the pharmaceutical composition, when administered to the individual, causes an improvement in near visual acuity.

113. The use according to any one of claims 98 to 106, wherein the pharmaceutical

composition, when administered to the individual, causes an improvement in intermediate visual acuity.

114. The use according to any one of claims 98 to 106, wherein the pharmaceutical composition, when administered to the individual, causes an improvement in distance visual acuity.

115. The use according to any one of claims 112 to 114, where in the improvement in visual acuity is an at least 2-line improvement.

116. The use according to any one of claims 112 to 114, where in the improvement in visual acuity is an at least 3-line improvement.

117. The use according to any one of claims 109 to 116, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 1 hour.

118. The use according to any one of claims 109 to 114, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 2 hours.

119. The use according to any one of claims 109 to 114, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 4 hours.

120. The use according to any one of claims 109 to 114, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 6 hours.

121. The use according to any one of claims 109 to 114, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 9 hours.

122. The use according to any one of claims 109 to 114, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 10 hours.

123. The use according to any one of claims 109 to 114, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 12 hours.

124. The use according to any one of claims 109 to 123, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 200 cd/m^2.

125. The use according to any one of claims 102 to 123, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 150 cd/m^2.

126. The use according to any one of claims 102 to 123, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 100 cd/m^2.


127. The use according to any one of claims 102 to 123, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 50 cd/m^2.

128. The use according to any one of claims 102 to 123, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 10 cd/m^2.

129. The use according to any one of claims 102 to 123, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 5 cd/m^2.

130. The use according to any one of claims 102 to 123, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 2 cd/m^2.

131. Use of a compound of Formula I:



Formula I

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an ocular condition in an individual in need thereof, wherein the medicament is a pharmaceutical composition according to any one of claims 1 to 31, and wherein the ocular condition is selected

from the group consisting of presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and night myopia.

132. The use according to claim 131, wherein the ocular condition is presbyopia.

133. The use according to claim 131, wherein the ocular condition is poor night vision.

134. The use according to claim 131, wherein the ocular condition is visual glare.

135. The use according to claim 131, wherein the ocular condition is visual starbursts.

136. The use according to claim 131, wherein the ocular condition is visual halos.

137. The use according to claim 131, wherein the ocular condition is night myopia.

138. The use according to any one of claims 131–137, wherein the medicament, when administered to the individual, is administered to one or both eyes of the individual.

139. The use according to claim 138, wherein the administration to the eye is topical administration.

140. The use according to any one of claims 131 to 139, wherein the amount of the compound of Formula I or pharmaceutically acceptable salt thereof in the medicament, when administered to the individual, has binding to the iris pigment that is less than the binding to the iris pigment exhibited by brimonidine.

141. The use according to any one of claims 131 to 139, wherein the amount of the compound of Formula I or pharmaceutically acceptable salt thereof in the medicament is an amount that is less than the amount of brimonidine needed to achieve the same therapeutic effects.

142. The use according to any one of claims 131 to 139, wherein the medicament, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of between 2 and 3 mm.

143. The use according to any one of claims 131 to 139, wherein the medicament, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is

constricted to a size of 3 mm or less.

144. The use according to any one of claims 131 to 139, wherein the medicament, when administered to the individual, causes an amount of reduction in pupil size such that the pupil is constricted to a size of 2.5 mm or less.

145. The use according to any one of claims 131 to 139, wherein the medicament, when administered to the individual, causes an improvement in near visual acuity.

146. The use according to any one of claims 131 to 139, wherein the medicament, when administered to the individual, causes an improvement in intermediate visual acuity.

147. The use according to any one of claims 131 to 139, wherein the medicament, when administered to the individual, causes an improvement in distance visual acuity.

148. The use according to any one of claims 145 to 147, where in the improvement in visual acuity is an at least 2-line improvement.

149. The use according to any one of claims 145 to 147, where in the improvement in visual acuity is an at least 3-line improvement.

150. The use according to any one of claims 142 to 149, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 1 hour.

151. The use according to any one of claims 142 to 149, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 2 hours.

152. The use according to any one of claims 142 to 149, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 4 hours.

153. The use according to any one of claims 142 to 149, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 6 hours.

154. The use according to any one of claims 142 to 149, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 9 hours.

155. The use according to any one of claims 142 to 149, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 10 hours.

156. The use according to any one of claims 142 to 149, wherein the reduction in pupil size or improvement in visual acuity is maintained for at least 12 hours.

157. The use according to any one of claims 142 to 156, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 200 cd/m^2.

158. The use according to any one of claims 142 to 156, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 150 cd/m^2.

159. The use according to any one of claims 142 to 156, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 100 cd/m^2.

160. The use according to any one of claims 142 to 156, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 50 cd/m^2.


161. The use according to any one of claims 142 to 156, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 10 cd/m^2.

162. The use according to any one of claims 142 to 156, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 5 cd/m^2.

163. The use according to any one of claims 142 to 156, wherein the reduction in pupil size or improvement in visual acuity is achieved when the individual is exposed to luminance levels of less than 2 cd/m^2.

164. A pharmaceutical composition substantially as described herein.

165. A pharmaceutical composition comprising a compound of Formula I:




Formula I

or a pharmaceutically acceptable salt thereof, a buffer, sodium chloride, and water substantially as described herein.

166. A method of treating an ocular condition selected from the group consisting of presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and night myopia substantially as described herein.

167. A method of treating an ocular condition selected from the group consisting of presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and night myopia with a pharmaceutical composition substantially as described herein.

168. A method of using pharmaceutical composition comprising a compound of Formula I:



Formula I

or a pharmaceutically acceptable salt thereof, a buffer, sodium chloride, and water substantially as described herein.